There are two models to account for the large population of GPI-negative cells and the occasional demonstration of oligoclonality in paroxysmal nocturnal hemoglobinuria (PNH): i) immune escape; 1 and ii) hypermutability. In support of immune escape, in PNH, marrow failure is common and is associated with HLA-DR alleles and oligoclonal T-cell expansions. Conversely, in support of hypermutability, there is an increased relative risk of leukemia, and cytogenetic abnormalities 2 and secondary mutations 3, 4 can occur. Others have reported an increased frequency of HPRT-mutants, 5, 6 a possible consequence of increased lymphocyte turnover, rather than hypermutability. 7 We previously showed that GPI + cells from patients with PNH demonstrate no increase in the mutation rate in the PIG-A gene itself. 8 However, these prior studies, including our own, utilized lymphoid cells, whereas PNH is a stem cell disorder particularly affecting the myeloid/erythroid lineages.
Here we have applied our analysis 9 for spontaneously arising phenotypic variants using XK, the gene mutated in the McLeod syndrome, 10 to explore this question. This assay has several advantages: 1) XK is X-linked, as are PIG-A and HPRT, and thus a single mutation can produce the mutant phenotype; 2) a broad spectrum of mutations 11 can inactivate the gene; 3) the XK mutant (McLeod) phenotype results in a loss of Kell proteins on red blood cells (RBC), which is detected by flow cytometry. Patients and normal donors provided written informed consent.
Approximately 10 7 RBC from whole blood were incubated with 50 µL of MIMA91 supernatant (generated as described by Tearina et al.
12
) which recognizes a non-polymorphic human Kell antigen. The RBC were washed twice with cold HANKS with 0.1% BSA and incubated with Rphycoerythrin-conjugated F(ab')2 fragment rabbit antimouse immunoglobulin (Dako,1:5), washed twice, and incubated with anti-glycophorin-A-FITC (Dako, 1:10). We also analyzed thawed RBC from a patient with the McLeod syndrome and an obligate female carrier. Incubations were performed on ice for 30 min. Prior to each incubation, the cells were resuspended, pelleted, and resuspended. Some experiments used biotinylated anti-CD59 (Serotec,1:20) and streptavidin-PerCP-Cy5.5 (Becton-Dickinson,1:2.5). Cells were analyzed on a BD FACScan using Cellquest and Flow-Jo. Voltage was adjusted so that unstained RBC had a mean fluorescence of 2.5 on FL1 and FL2; RBC were gated by FSC/SSC (log-log scale) and glycophorin-A expression. Cells having less than 20% of the mean FL2 of the overall population were defined as McLeod-like. First, MIMA91 was validated using RBC derived from a patient with the McLeod syndrome, an obligate carrier, and a normal donor ( Figure 1A -C), and the patterns were similar to our previous data using an anti-K14 antibody. 9 In the normal donor, there is a distinct population of RBC with the McLeod-like phenotype at a frequency (f) of 31 x 10 -6
. Pre-treatment of RBC with dithiothreitol greatly attenuated Kell expression, as expected (data not shown).
Among 15 normal adult donors, in each, there was a distinct population of McLeod-like RBC; f ranged from 13.6 x 10 -6 to 113 x 10
, with a median of 48.3 x 10 -6 (Figure 1D-F). We then tested 17 patients; 13 had "classic" PNH ( ). As previously shown, 9 f was lower (15 x 10 -6 , range 11-36.9 x 10 -6 ) among 5 cord blood samples (P<0.006, two-sided non-parametric test) compared to the group of normal donors and patients. We then analyzed an additional 7 patients by gating separately on CD59 -and CD59 + RBC; f was 17.8 x 10 -6 for the CD59-population (range 9.4-346 x 10 -6 ) and 27.2 x 10 -6 (range 6.4-46.8 x 10 -6 ) for the CD59 + population (P=NS, signed rank sum test). For Patient 18, f was 7.4-fold higher in the CD59 -population than for the CD59 + population. For Patient 20, there was a 4.6-fold difference in the opposite direction. For the others, the difference was less than 4-fold. We did not identify any clinical features that were associated with the fold difference in the f values among these 7 patients.
Since hypermutability would have to occur in the stem cell→erythroid differentiation pathway to account for PNH, we believe these data using RBC argue strongly against hypermutability. The frequency of McLeod-like RBC in PNH is similar to that of normal donors, and comparable to other mutation reporter genes. [13] [14] [15] Gating specifically on the CD59 -RBC did not overall enrich for McLeod-like cells, arguing against mosaicism for hypermutability. Of note, for both XK and PIG-A, a broad spectrum of mutations, including very large deletions, can inactivate the gene, they are of similar length, and have a similar number of sites where a T→G transversion or a demethylation at CpG would produce a stop codon. Therefore, there is no reason to suspect that XK is less susceptible to spontaneous mutagenesis than PIG-A.
In a study involving spontaneous loss of GPA alleles, 16 it was demonstrated that, among normal donors, the frequency of GPA variants ranged from 0 to 20 x 10 -6 ; among 9 PNH patients, 3 were above this range, and only one was a clear outlier. In our study, Patients 17 and 18 may represent outliers. Of note, we did not specifically study subsets with JAK2 mutations, 4 complex cytogenetic abnormalities, or multiple PNH clones. However, 8 had separate PNH II and PNH III populations, and most had large PNH populations; if hypermutability were important, we should have seen it in such patients. Another caveat is that we have not yet defined the pathological conditions for which the frequency of McLeod-like cells is definitively elevated, and since RBC are enucleated, it will not be easy to identify the corresponding XK mutations. In our work using dividing cells, 8 we could measure the mutation rate, whereas here, with erythrocytes, we must rely upon the mutant frequency as a surrogate. Indeed, it is possible that the kinetics of cell division in stem cells and red cell precursors will be different in patients with PNH due to marrow injury on one hand, and compensation for hemolytic anemia on the other. Despite these caveats, these data support the view that, in most (if not all) patients with PNH, there is another process rather than hypermutability that is the primary cause of expanded PIG-A-mutant populations.
